Yamashita et al. (2015) analyzed blood flow and genetic status in 66 patients with glioblastomas using pulsed PASL technology (55 with wildtype gliomas and 11 with IDH1 mutation), while the perfusion study was performed only in 43 patients (34 in patients with wildtype glioblastomas and 9 with mutant forms of glioblastomas) [26]. The gene discussed is IDH1; the disease is central nervous system cancer.